Familial Hypercholesterolemia
Obicetrapib tied to sizable LDL lowering on top of other therapies in high-risk patients
CHICAGO — In patients with heterozygous familial hypercholesterolemia with high LDL despite being on optimal medical therapy, obicetrapib greatly lowered LDL levels compared with placebo, according to the results of the BROOKLYN trial.
Managing high cholesterol during pregnancy ‘challenging,’ medications lack safety data
Most lipid-lowering medications lack safety data for pregnant and lactating women, complicating management of hyperlipidemia and hypertriglyceridemia, but data suggest statins can be used for those at high risk for cardiovascular events.
2018 ACC/AHA Multi-Society Cholesterol Guideline Overview
NLA document issued to optimize screening, management of lipids in reproductive-age women
The National Lipid Association has issued a clinical consensus statement on the management of dyslipidemia in women of reproductive potential, with a focus on considerations for pharmacologic options, a speaker reported.
Ace the Case #3: A 54-Year-Old South Asian Male with a History of Cardiac Percutaneous Intervention
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Ace the Case #2 - A 62-Year-Old Woman with Diabetes with an LDL-C of 53 mg/dL
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Ace the Case #1 – A 34-Year-Old Woman with Severe Heterozygous Familial Hypercholesterolemia (HeFH)
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Ballantyne: Prevention of heart disease crucial, core of NLA’s mission
Prevention of heart disease will do more good in the long run than procedures to treat advanced heart disease, the incoming president of National Lipid Association said at the NLA’s Scientific Sessions.
‘Elevated Lp(a) is actionable now’: NLA issues updated recommendations
The National Lipid Association issued a focused update on its 2019 scientific statement on use of lipoprotein(a) in clinical practice, incorporating new evidence into recommendations for managing patients with high Lp(a).
FDA approves expanded indications for bempedoic acid and combination tablet
Esperion announced the FDA granted an updated indication for bempedoic acid and bempedoic acid plus ezetimibe for the treatment of primary hyperlipidemia in eligible patients with genetic hyperlipidemia or atherosclerotic CVD.